Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
about
Targeted DNA mutagenesis for the cure of chronic viral infectionsEffect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group studyRelationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failureThe ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?Illustration of a measure to combine viral suppression and viral rebound in studies of HIV therapyOptimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor SettingsCYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, HaitiModeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching timesAssociation between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG).Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.Efavirenz in the therapy of HIV infection.African American race and HIV virological suppression: beyond disparities in clinic attendance.Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine careThe non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial dataSecondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysisGenetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268.Short-term discontinuation of HAART regimens more common in vulnerable patient populations.Assessing the performance of a computer-based policy model of HIV and AIDSPharmacogenetics of drug hypersensitivity.48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV.Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095Factors associated with remaining on initial randomized efavirenz-containing regimens.No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants.Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort studyA randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysisGenome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort studyPhenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy.Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapySocial and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy.Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism
P2860
Q24620150-1F545187-0879-4E34-AC94-60C6976B2161Q24633579-3A6BF661-FCC6-4E5C-92C2-E2C5D3688956Q27003431-88245084-8A2A-47D3-B911-A276C58486E9Q27030892-559CC6FB-12D7-4EDC-9A77-129DD606017DQ28385909-1F281808-B116-4B80-AD0C-2E61DE446620Q28547109-B7B00864-0427-45E4-94E9-D63A37F19BAFQ30438405-3B1E0EA4-1B58-4581-BDEB-2842FFA078B2Q30655744-0BEF3E43-AACD-402C-BE5B-EF00D371E76DQ30834094-C844204B-A24D-4532-9A86-C19A1FF92B47Q31037300-AD747123-D7B1-42BB-A452-EC11EC235D15Q31118978-FC9B1B2E-A7DF-4D73-B661-CA1E939786FEQ33313038-7D47DE4B-CA3B-4FAD-AF31-6F75E3A3417CQ33607011-3F366B30-D7DC-461F-9F2B-EA60AD5BE0B4Q33735032-5F13E035-77A7-432A-B647-72EEE562A7DCQ33766361-448B5917-D169-464B-A31C-82169FCA6748Q33872810-1482A14E-7452-42FC-9529-A52053C12BE6Q33891656-B68C4279-AC43-44A6-8B01-6D2035A0812BQ33909996-C9352817-FD8C-4E71-9462-E80EA90FD7E8Q33950833-DF5CA235-7CF2-4B86-93E1-C1F2E54B29F4Q33988391-BB6AF8B8-4867-4867-8F27-C9A1706DDD44Q34085103-11B57C5C-C75C-44B6-A2AA-C235D8196199Q34115343-8C8705E0-EB6B-49C2-B2B5-FA732190B48DQ34118186-12B4919E-F0C7-4D2D-AF9F-9B524A3FD7BEQ34134900-4558460E-CE41-4CB6-92A4-F79DDDA16A03Q34201445-BB79A322-FBA9-4D45-8030-11CBD26064FFQ34216364-463EDE08-DD2F-4A82-A3F6-1F660C41CE9DQ34287573-2227C571-B148-4D88-AC67-2A2E944E56C3Q34378368-161CFA29-A1DA-4F43-861F-575ACB4D6F36Q34708243-51F57B39-EDAF-4AAB-9A9C-7764867C0922Q34982530-28CE0A22-A264-499E-9E61-F6892FFC9143Q34988296-35ED3C56-2B7F-48AA-A751-5CAE359EFC6AQ35024683-F16734C4-F511-4D27-AC2F-2F94F9C01B0AQ35063571-6D801ACE-E863-438A-970C-A360CE270FA4Q35288691-96B5ECCC-A46C-4434-8900-01453D07EF03Q35386113-05010AE0-B3E8-478A-AB65-FCF6252D5DB8Q35408073-4BA41C09-6759-44C8-8665-239CA1057EA4Q35452380-294D7CA9-6EA2-43D5-A237-0396EDAD6A7BQ35466014-D36B9B5E-43BD-4194-B3FF-A63CB274F41DQ35823204-CAF63290-2451-4872-BF35-0EBB6AF1F493Q35846917-E8629EC8-E280-44BE-9A06-1E8B5E4CAA6B
P2860
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Three- vs four-drug antiretrov ...... a randomized controlled trial.
@en
type
label
Three- vs four-drug antiretrov ...... a randomized controlled trial.
@en
prefLabel
Three- vs four-drug antiretrov ...... a randomized controlled trial.
@en
P2093
P356
P1476
Three- vs four-drug antiretrov ...... a randomized controlled trial.
@en
P2093
AIDS Clinical Trials Group (ACTG) A5095 Study Team
Barbara Bastow
Bruce R Schackman
Cecilia M Shikuma
Christina Lalama
Christopher D Pilcher
Daniel R Kuritzkes
Edward P Acosta
Heather J Ribaudo
Jeffrey Schouten
P304
P356
10.1001/JAMA.296.7.769
P407
P577
2006-08-01T00:00:00Z